Advertisement
Canada markets open in 47 minutes

  • S&P/TSX

    21,554.86
    -26.44 (-0.12%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.53 (+0.04%)
     

  • CAD/USD

    0.7306
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    80.99
    +0.26 (+0.32%)
     

  • Bitcoin CAD

    83,731.23
    -4,318.61 (-4.90%)
     

  • CMC Crypto 200

    1,267.51
    -42.21 (-3.22%)
     

  • GOLD FUTURES

    2,338.80
    +7.60 (+0.33%)
     

  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     

  • 10-Yr Bond

    4.2670
    +0.0100 (+0.23%)
     

  • NASDAQ futures

    19,957.75
    -25.00 (-0.13%)
     

  • VOLATILITY

    13.77
    +0.57 (+4.32%)
     

  • FTSE

    8,276.35
    +38.63 (+0.47%)
     

  • NIKKEI 225

    38,804.65
    +208.18 (+0.54%)
     

  • CAD/EUR

    0.6807
    -0.0019 (-0.28%)
     
MARKETS LIVE BLOG:

STOCK FUTURES INCH UP AS HIGH-FLYING Q2 NEARS CLOSE

S&P 500 is up around 4.5% this quarter, while the Nasdaq has surged about 8%

Savara Announces New Employment Inducement Grant

Business Wire
·2 min read

AUSTIN, Texas, May 16, 2024--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.

On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 15,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 2,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee’s acceptance of employment with the Company.

The options have an exercise price of $4.81 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date. Each option has a 10-year term and vests as to 1/16th of the number of shares subject to the option on each quarterly anniversary of the employee’s first day of employment, subject to the employee’s continued employment on each such vesting date. The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date.

ADVERTISEMENT

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240516493943/en/

Contacts

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366